Reaction
Paraneoplastic Syndrome reporting signals
As of the last recalculation, Paraneoplastic Syndrome appears in 669 FAERS reports alongside 15 co-occurring drug terms. The strongest observed disproportionality signal is PEMETREXED (PRR 25.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Pemetrexed | 17 | 25.3 | 25.3 |
| Pemetrexed Disodium | 28 | 23.8 | 23.8 |
| Gefitinib | 5 | 17.4 | 17.4 |
| Pembrolizumab | 54 | 17.3 | 17.3 |
| Baricitinib | 5 | 16.2 | 16.3 |
| Bleomycin Sulfate | 5 | 15.2 | 15.2 |
| Erlotinib Hydrochloride | 6 | 15.0 | 15.0 |
| Cisplatin | 32 | 13.3 | 13.3 |
| Carboplatin | 50 | 13.2 | 13.2 |
| Inclisiran | 3 | 11.7 | 11.7 |
| Pazopanib Hydrochloride | 10 | 11.7 | 11.7 |
| Nivolumab | 34 | 11.5 | 11.5 |
| Atezolizumab | 14 | 11.4 | 11.4 |
| Durvalumab | 7 | 10.8 | 10.8 |
| Crizotinib | 4 | 9.8 | 9.8 |